US0463531089
© BusinessWire
22.12.2025
AZN
LISTED
NASDAQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
News Preview
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence.
The Food...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
AZN
LISTED
NASDAQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
News Preview
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, as determined by a Food and Drug Administration (FDA)-approved test.
The approval follows Priority Review a...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
AZN
LISTED
NASDAQ
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
News Preview
AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6-9, 2025.
This year’s ASH congress will feature the Company’s largest presence to date, with 65 abstracts across eight approved and investigat...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
02.12.2025
AZN
LISTED
NASDAQ
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
News Preview
AstraZeneca’s New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
26.11.2025
AZN
LISTED
NASDAQ
IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
News Preview
AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the US for the treatment of adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The approved r...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2025
AZN
LISTED
NASDAQ
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
News Preview
AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecul...
Themefolio
Profiler
Peergroup
© BusinessWire
09.11.2025
AZN
LISTED
NASDAQ
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
News Preview
Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
AZN
LISTED
NASDAQ
Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
News Preview
Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in hypereosinophilic syndrome (HES),1 a rare disease driven by elevated eosinophils.2 These data will be presented at the American College of Allergy, Asthma and Im...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
AZN
LISTED
NASDAQ
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
News Preview
Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as 1st-line treatment...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
AZN
LISTED
NASDAQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
News Preview
Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) in patients with a high risk of disease recurrence. The trial compared ENHERTU with trastuzumab emtansine (T-DM1)...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
AZN
LISTED
NASDAQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
News Preview
Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before surgery) demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response (pCR) rate. The trial co...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
AZN
LISTED
NASDAQ
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
News Preview
AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a complex epithelial-driven inflammatory condition. TEZSPIRE is the first and only biologic th...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
17.10.2025
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
News Preview
Positive results from the POTOMAC Phase III trial showed adding one year of treatment with AstraZeneca’s IMFINZI® (durvalumab) to BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with BCG-naïve, high-risk non-muscle-invasive bladder canc...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
News Preview
Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of ov...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
AZN
LISTED
NASDAQ
AstraZeneca unveils expanded manufacturing facility in Texas
News Preview
AstraZeneca today announces the unveiling of its newly-expanded, state-of-the-art manufacturing facility in Coppell, Texas. The expansion project will double the production of Lokelma for the benefit of patients in the United States and around the world.
The investment of $445 million to expand the facility follows the groundbreaking last week a...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
AZN
LISTED
NASDAQ
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
News Preview
AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October 17-21, 2025.
More than 95 abstracts will feature nine approved and nine potential new medicines from the Company including two abstracts featured...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2025
AZN
LISTED
NASDAQ
AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
News Preview
AstraZeneca today announces that it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500m to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments. This is part of the historic $50 billion investment announced in July 2025. The new facility will be l...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
AZN
LISTED
NASDAQ
Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
News Preview
Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Efficacy was observed throughout the 24-hour period, including early morning, when patients w...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
AZN
LISTED
NASDAQ
DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02
News Preview
Positive high-level results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as 1st-line...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2025
AZN
LISTED
NASDAQ
AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
News Preview
AstraZeneca today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent cash price with home delivery. AstraZeneca Direct will support people living with chronic conditions such as asthma, diabetes, heart failure and c...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
AZN
LISTED
NASDAQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
News Preview
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been accepted and granted Priority Review in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
The Food and Drug Admini...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2025
AZN
LISTED
NASDAQ
AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
News Preview
AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma.1 The BATURA Phase IIIb trial, which evaluated severe exacerbation risk reduction, examined the efficacy of as-needed AIRSUPRA compared to as-needed albuterol,2 the most commonly used rescue medication for asthma in...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
AZN
LISTED
NASDAQ
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
News Preview
Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration of AstraZeneca’s SAPHNELO® (anifrolumab) demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to...
Themefolio
Profiler
Peergroup
© BusinessWire
07.09.2025
AZN
LISTED
NASDAQ
TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
News Preview
Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to TAGRISSO monotherap...
Themefolio
Profiler
Peergroup
© BusinessWire
30.08.2025
AZN
LISTED
NASDAQ
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial
News Preview
Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. Results were seen in patients with hard-to-control (uncontrolled and resistant) hypertensio...
Themefolio
Profiler
Peergroup
© BusinessWire
15.08.2025
AZN
LISTED
NASDAQ
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery
News Preview
AstraZeneca today launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST® (Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.1
This press...
Themefolio
Profiler
Peergroup
© BusinessWire
28.07.2025
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
News Preview
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
The Food and Drug Administration (FDA) grants...
Themefolio
Profiler
Peergroup
© BusinessWire
21.07.2025
AZN
LISTED
NASDAQ
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
News Preview
AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for p...
Themefolio
Profiler
Peergroup
© BusinessWire
21.07.2025
AZN
LISTED
NASDAQ
TAGRISSO® (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer
News Preview
Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to TAGRISSO...
Themefolio
Profiler
Peergroup
© BusinessWire
14.07.2025
AZN
LISTED
NASDAQ
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
News Preview
Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or...
Themefolio
Profiler
Peergroup
© BusinessWire
24.06.2025
AZN
LISTED
NASDAQ
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
News Preview
DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.
This indication is approved under accelerated approval based on objective respon...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
AZN
LISTED
NASDAQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
News Preview
Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and pertuzumab (THP) as a 1st-line treatment for patients with HER2-p...
Themefolio
Profiler
Peergroup
© BusinessWire
01.06.2025
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
News Preview
Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-fr...
Themefolio
Profiler
Peergroup
© BusinessWire
01.06.2025
AZN
LISTED
NASDAQ
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
News Preview
Positive results from the SERENA-6 Phase III trial showed that AstraZeneca’s camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS). The trial evaluated switching...
Themefolio
Profiler
Peergroup
© BusinessWire
21.05.2025
AZN
LISTED
NASDAQ
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
News Preview
AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 to June 3, 2025.
More than 80 abstracts will feature 20 approved and potential new medicines from the Company including two p...
Themefolio
Profiler
Peergroup
© BusinessWire
19.05.2025
AZN
LISTED
NASDAQ
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
News Preview
Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and clinically meaningful improvements in all primary and secondary endpoints compared to albuterol in patients with mild asthma.1,2 These data were published...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
AZN
LISTED
NASDAQ
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
News Preview
AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Francisco, CA from May 16 to 21, 2025.
With more than 75 abstracts, including eight late-breakers, the Company continues to drive inno...
Themefolio
Profiler
Peergroup
© BusinessWire
09.05.2025
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
News Preview
Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca’s IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
AZN
LISTED
NASDAQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
News Preview
Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin an...
Themefolio
Profiler
Peergroup
© BusinessWire
02.05.2025
AZN
LISTED
NASDAQ
BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
News Preview
Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically mea...
Themefolio
Profiler
Peergroup
© BusinessWire
21.04.2025
AZN
LISTED
NASDAQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
News Preview
Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and pertuzuma...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
AZN
LISTED
NASDAQ
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
News Preview
Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo.1,2 AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
News Preview
AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).
The approval was granted by the...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
AZN
LISTED
NASDAQ
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
News Preview
New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Highlights include...
Themefolio
Profiler
Peergroup
© BusinessWire
14.03.2025
AZN
LISTED
NASDAQ
AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
News Preview
AstraZeneca and Erin Andrews have teamed up as part of a national public health campaign to educate and empower people to Get Body Checked Against Cancer. Erin is a passionate entrepreneur, national sports broadcaster, podcast host, hockey fan and wife — and cancer survivor.
This press release features multimedia. View the full release here: https...
Themefolio
Profiler
Peergroup
© BusinessWire
07.03.2025
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers
News Preview
Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint...
Themefolio
Profiler
Peergroup
© BusinessWire
01.03.2025
AZN
LISTED
NASDAQ
Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
News Preview
Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo.1,2 These data were published in the...
Themefolio
Profiler
Peergroup
© BusinessWire
26.02.2025
AZN
LISTED
NASDAQ
Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
News Preview
Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in the primary endpoint o...
Themefolio
Profiler
Peergroup
© BusinessWire
21.02.2025
AZN
LISTED
NASDAQ
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) and reminds investors of the Feb. 21, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi &...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
AZN
LISTED
NASDAQ
AZN Deadline: Rosen Law Firm Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm – AZN
News Preview
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
So what: If you purchased Ast...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
AZN
LISTED
NASDAQ
Deadline Soon: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming February 21, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024, inclusive...
Themefolio
Profiler
Peergroup
© BusinessWire
14.02.2025
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
News Preview
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab), administered perioperatively in combination with neoadjuvant chemotherapy, demonstrated improvements in event-free survival (EFS) and overall survival (OS) versus neoadjuvant chemotherapy with radical cystectomy alone...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
AZN
LISTED
NASDAQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
News Preview
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by a Food and Drug Administration (...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2025
AZN
LISTED
NASDAQ
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
News Preview
DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. The approval by t...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2025
AZN
LISTED
NASDAQ
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
News Preview
AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
The approval was granted by the Food and Drug Administration (FDA)...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
AZN
LISTED
NASDAQ
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
News Preview
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have received prior system...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
AZN
LISTED
NASDAQ
Deadline Alert: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming February 21, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024, inclusive (the “...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
AZN
LISTED
NASDAQ
Deadline Approaching: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming February 21, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”).
IF YOU ARE AN...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
AZN
LISTED
NASDAQ
AZN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AstraZeneca PLC (NASDAQ: AZN) publicly traded securities between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”), have until February 21, 2025 to seek appointment as lead plaintiff of the AstraZeneca class action lawsuit. Captioned Sal...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
AZN
LISTED
NASDAQ
Law Offices of Frank R. Cruz Encourages AstraZeneca PLC (AZN) Investors To Inquire About Securities Fraud Class Action
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”). AstraZeneca investors have until February 21, 2025 to file a lead plain...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
